Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GH Research ( (GHRS) ) has shared an announcement.
On July 31, 2025, GH Research PLC held its annual general meeting where shareholders approved all board-recommended resolutions. These included the re-election of key directors and the ratification of PricewaterhouseCoopers Ireland as auditors for 2025. The meeting also renewed the board’s authority to issue shares, impacting the company’s strategic financial operations.
The most recent analyst rating on (GHRS) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on GH Research stock, see the GHRS Stock Forecast page.
Spark’s Take on GHRS Stock
According to Spark, TipRanks’ AI Analyst, GHRS is a Neutral.
GH Research’s stock score reflects significant challenges in financial performance, with consistent losses and negative cash flows. The company’s strong equity base and low debt provide some stability. Technical indicators show some short-term momentum, but valuation concerns persist due to the negative P/E ratio and lack of profitability.
To see Spark’s full report on GHRS stock, click here.
More about GH Research
GH Research PLC operates in the pharmaceutical industry, focusing on the development of innovative treatments for mental health disorders.
Average Trading Volume: 236,874
Technical Sentiment Signal: Buy
Current Market Cap: $890.7M
For a thorough assessment of GHRS stock, go to TipRanks’ Stock Analysis page.